News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2014

Results of Adherence Study Published in BMC Gastroenterology Demonstrate that Epigenomics’ Blood-based Epi proColon® Improves Compliance to CRC Screening

27.10.2014 | PDF Berlin (Germany) and Germantown, MD (U.S.A) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced the publication of the results of a trial assessing the impact of a non-invasive blood-based test on patient adherence to colorectal cancer (CRC) screening. The peer-reviewed article titled “Improving compliance […]

Read more

Epigenomics AG raises USD 5.3 million from its strategic commercialization partner BioChain

16.10.2014 | 141016_Press_release_Epigenomics_AG_capital_increase Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.), Beijing (China), October 16, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company is raising USD 5.3 million (EUR 4.2 million) in a share capital increase. BioChain Institute, Inc. will subscribe a […]

Read more

Ad hoc: Epigenomics raises USD 5.3 million from its strategic commercialization partner BioChain

Berlin (Germany) and Germantown (USA), October 16, 2014 – Epigenomics AG (ISIN: DE000A11QW50, OTCQX: EPGNY) announces today that the Company is raising USD 5.3 million (EUR 4.2 million) in a share capital increase. BioChain Institute, Inc. will subscribe a total of 1,351,089 Epigenomics shares which will be issued under exclusion of the statutory subscription right […]

Read more

Epigenomics Provides Corporate Update

PDF 74 KB Berlin (Germany) and Germantown, MD (U.S.A.) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today provides a corporate update on major developments.

Read more

Epigenomics AG converts to registered shares

PDF 68 KB   Berlin (Germany), Germantown, MD (U.S.A.), September 19, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, will convert its 13,510,892 bearer shares into registered shares effective Monday, September 22, 2014 at a ratio of 1:1.

Read more

Epigenomics AG Announces H1 2014 and Q2 2014 Financial Results and Reports on Operational Highlights

PDF 253 KB   Berlin (Germany) and Germantown, MD (U.S.A.) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the second quarter and the first half of 2014 ending June 30.

Read more